Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (13437)	10/11/2004 11:12:23 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

could lead to gaming, if you have good phenotype data I'm assuming that the resultant label would only have approval for the identifiable target population. Hoff made the point that if you look at existing drugs, approvals were based on a very limited number of actual complete responses (between 6 and 80 with a median of 24) even though there were thousands of patients in the trials. So it's not crazy to say "bring us 25 CR's out of 275 patients" and we'll approve the drug. Peter